MENU

Alzheimer's & Dementia

About this condition
Patient & Caregiver Tools
Show More
Articles
Physical and Cognitive Activity for Dementia image

Cover Focus

Physical and Cognitive Activity for Dementia

There is enough evidence of the neuroprotective effects of physical and cognitive activity to recommend these to patients.

Ajay Sood, MD, PhD, and David Bennett, MD

Neurofilament Light as a Dementia Biomarker image

Cover Focus

Neurofilament Light as a Dementia Biomarker

An emerging versatile blood biomarker may help identify neurodegenerative diseases and help track disease progression and treatment response.

Julio C. Rojas, MD, PhD

Blood Tests for Alzheimer Disease image

Cover Focus

Blood Tests for Alzheimer Disease

Blood tests for Alzheimer disease are moving toward clinical implementation and interpretation.

Henrik Zetterberg, MD, PhD; Deborah O.T. Alawode, BSc; Ashvini Keshavan, MRCP, PhD; Antoinette O’Connor, MRCPI; Philip S. J. Weston, MRCP, PhD; Ross W. Paterson, MRCP, PhD; Amanda Heslegrave, PhD; Nick C. Fox, MD, FRCP, FMedSci; Michael P. Lunn, FRCP, PhD; and Jonathan M. Schott, MD, FRCP

Quantitative Structural MRI for Neurocognitive Disorders image

Cover Focus

Quantitative Structural MRI for Neurocognitive Disorders

Alzheimer disease dementia, frontotemporal dementia, and traumatic brain injury can be differentiated with quantitative MRI.

Cyrus A. Raji, MD, PhD; Somayeh Meysami, MD; and Mario F. Mendez, MD, PhD

Molecular Imaging Biomarkers in Dementia image

Cover Focus

Molecular Imaging Biomarkers in Dementia

Amyloid and tau PET imaging aids evaluation of patients suspected of having Alzheimer disease or other dementias.

Brad Dickerson, MD, and Alireza Atri, MD, PhD

Digital Cognitive Assessments for Dementia image

Cover Focus

Digital Cognitive Assessments for Dementia

Digital assessments may enhance the efficiency of evaluations in neurology and other clinics.

Adam M. Staffaroni, PhD; Elena Tsoy, PhD; Jack Taylor, BS; Adam L. Boxer, MD, PhD; and Katherine L. Possin, PhD

Naturalistic Driving Measures image

Cover Focus

Naturalistic Driving Measures

Naturalistic driving measurement serves as a functional marker for preclinical and symptomatic Alzheimer disease.

Ganesh M. Babulal, PhD, OTD, and Catherine M. Roe, PhD

Dementia Innovations image

Guest Medical Editor's Page

Dementia Innovations

After years in development, many innovations are poised to move into clinical practice.

Nupur Ghoshal, MD, PhD

News

11.19.20

Retinal Amyloid Imaging for Detecting Alzheimer Progression
  • KEYWORDS:
  • Alzheimer Disease
  • Amyloid
  • Neuro-ophthalmology

News

11.10.20

Azeliragon Studies for Treatment of Alzheimer Disease In People With Type II Diabetes Continue
  • KEYWORDS:
  • Alzheimer Disease
  • Azeliragon
  • Mild cognitive impairment
  • Type 2 Diabetes

News

11.09.20

Neflamapimod Improves Cognition in Dementia With Lewy Bodies in Phase 2 Trial
  • KEYWORDS:
  • Dementia
  • Lewy body dementia
  • Neflamapimod
  • Parkinson disease
  • Parkinson disease psychosis

Don Kent Describes Some of the Challenges of Living with Lewy Body Dementia

News

11.03.20

PDE4D Inhibitor Improves Cognition for People With Fragile X Syndrome in Phase 2 Trial
  • KEYWORDS:
  • Fragile X Syndrome
  • Mild cognitive impairment
  • PDE4D Inhibitor
  • Phase 2 clinical trial
Dementia Insights: Primary Prevention of Dementia image

Columns

Dementia Insights: Primary Prevention of Dementia

Evidence for modifiable lifestyle factors for dementia prevention is growing.

Chen Zhao, MD; Jonathan G. Hakun, PhD; Krishnankutty Sathian, MBBS, PhD; and Nikolaos Scarmeas, MD, MS, PhD

Epilepsy and Cognition image

Cover Focus

Epilepsy and Cognition

An Interview with Barbara C. Jobst, MD

Barbara C. Jobst, MD

News

10.01.20

First Dose of Potential Neuroprotective Agent Administered in Phase 2/3 Trial for Mild-to-Moderate AD
  • KEYWORDS:
  • Alzheimer Disease
  • Early onset Alzheimer disease
  • Phase 2/3 clinical trial

News

09.23.20

Supplements Claimed to Improve Concentration May Contain Unapproved Drugs
  • KEYWORDS:
  • Cognitive therapy
  • Concentration
  • FDA Approvals
  • FDA Unapproved
  • TBI
This Month's Issue
Physical and Cognitive Activity for Dementia

Ajay Sood, MD, PhD, and David Bennett, MD

Digital Cognitive Assessments for Dementia

Adam M. Staffaroni, PhD; Elena Tsoy, PhD; Jack Taylor, BS; Adam L. Boxer, MD, PhD; and Katherine L. Possin, PhD

Quantitative Structural MRI for Neurocognitive Disorders

Cyrus A. Raji, MD, PhD; Somayeh Meysami, MD; and Mario F. Mendez, MD, PhD